Volume 13, Number 1—January 2007
Model for Assessing Human Papillomavirus Vaccination Strategies
|12-y-old girls and boys||78,707,825||2,699,327||4,664,835||149||Dominated|
|12-y-old girls plus 12- to 24-y-old females catch-up||74,815,667||2,699,343||–3,892,159||16||4,666|
|12-y-old girls and boys plus 12− to 24-y-old females catch-up||79,746,357||2,699,461||4,930,690||118||41,803|
|12-y-old girls and boys plus 12− to 24-y-old females and males catch-up||81,761,210||2,699,506||2,014,853||45||45,056|
*Assumes cost of vaccination series is US $360 and duration of protection is lifelong. All costs are measured in 2005 US dollars, and costs and QALY are discounted at 3%. HPV, human papillomavirus; QALY, quality-adjusted life years.
†Compared with the preceding nondominated strategy. Strategy A is dominated if there is another strategy, B, that is more effective and less costly than strategy A.
- Page created: June 28, 2010
- Page last updated: June 28, 2010
- Page last reviewed: June 28, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)